| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01112306 | ACT-293987 in Pulmonary Arterial Hypertension | PHASE3 | COMPLETED | 709 | — | — | Jul 7, 2010 | Aug 26, 2021 | Mar 30, 2025 | 157 | United States, Argentina +36 |
| NCT00993408 | Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH) | PHASE2 | COMPLETED | 43 | — | — | Apr 30, 2008 | Jun 30, 2009 | Sep 12, 2025 | 8 | Austria, Belgium +6 |
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ACT-293987, twice daily |
| ACT-293987 (NS-304) and matching placebo | EXPERIMENTAL | Subjects will be randomized to the study following screening. Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304. |
| Name | Type | Description |
|---|---|---|
| ACT-293987 | DRUG | Tablets, twice daily |
| ACT-293987 (NS-304) | DEVICE | - |
Inclusion Criteria: * Patients who participated to the double-blind study AC-065A302 and either had a morbidity event or had completed the study as scheduled per protocol. * Signed informed consent. Exclusion Criteria: * Patients who have started receiving prostacyclin (epoprostenol) or prostacyc...